Reducing Biofilm in the Wound Bed of Deep Dermal Wounds Using a Novel Non-Biologic Topical Liquid Agent

Chronic wounds account for significant patient morbidity and has a major economic impact on the cost of healthcare. There are many causes for wounds to stall in the inflammatory phase, the development of biofilm plays a significant role in this process. Clinicians have increasingly adopted the widespread use of topical agents to manage chronic wound infection, despite limited data on their effectiveness in vivo.

This study sought to evaluate the evidence of a novel; topical, non-biologic technology employed to treat the biofilms of chronic wounds.

Regenerative Debridement Technology* (RDT) is a topical liquid agent for use by healthcare practitioners in the cleansing of lesions of the skin and damaged dermal tissue during standard mechanical debridement procedures. It removes necrotic tissue and destroys biofilm upon contact. This chemical process works on a unique non-biologic platform; mechanical, cellular, and molecular.

A Handheld Fluorescence Imaging Device** can instantly detect wound bed elevated bacterial loads. This device emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound bed to emit fluorescence.

This fluorescence signal is related to the components of the wound, including the presence of elevated bacterial loads. Certain bacteria species are well established in the literature to produce porphyrins and pyoverdines that emit red fluorescence. Bacterial loads more than 104 CFU/g typically correspond to those with moderate to heavy growth on a semi-quantitative scale.RDT* can be characterized by its functionality as clinical tool that was designed to perform controlled, intense, instantaneous water extraction from the top layer of necrotized tissue on a lesion surface. RDT* essentially is a therapeutic liquid used to instantaneously convert necrotized tissues, microbial biofilm and other proinflammatory pathogenic substances on the surface of a wound bed into harmless devitalized tissue coagulum.

Therefore, treatment of the wound bed with RDT* is intended to significantly mitigate biofilm on and in the wound bed. We intend to quantify this by the diagnostic use of the Handheld Fluorescence Imaging Device**.

Further studies will be forthcoming with additional diagnostic testing to evaluate the beneficial effects of RDT in wound bed preparation